MedTrace Logo

A Study Comparing Immediate Treatment to Deferred Treatment With the Fisher Wallace (FW) Stimulator FW-200 Device for the Treatment of Self-reported Anxiety in First Responders

NCT07093736 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2025-07-30

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if the Fisher Wallace Stimulator FW-200 experimental device is effective at treating self-reported anxiety in first responders. The main question the trial aims to answer is does the FW-200 device improve anxiety as measured by a validated questionnaire.

Conditions

Interventions

DEVICE

FW-200

Non-invasive, home-use neurostimulation device delivering transcranial fixed output, alternating current stimulation

Sponsors & Collaborators

  • Advarra

    collaborator INDUSTRY

  • Florence Healthcare

    collaborator UNKNOWN

  • Fisher Wallace Laboratories

    lead INDUSTRY

Principal Investigators

  • Lois James, Ph.D. · James Consulting

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-06
Primary Completion
2023-05-11
Completion
2023-05-11
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07093736 on ClinicalTrials.gov